Comparative Pharmacology
Head-to-head clinical analysis: FAMVIR versus FAVLYXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FAMVIR versus FAVLYXA.
FAMVIR vs FAVLYXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Famciclovir is a prodrug that is rapidly converted to penciclovir, which inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate, thereby inhibiting viral DNA synthesis and replication.
Acyclic nucleoside phosphonate prodrug that inhibits viral RNA-dependent RNA polymerase (RdRP) by competing with adenosine triphosphate (ATP). It incorporates into nascent viral RNA causing chain termination after incorporation of the first 1-2 nucleotides.
250 mg orally three times daily for 7 days for herpes zoster; 125 mg orally twice daily for 5 days for recurrent genital herpes; 250 mg orally twice daily for 7 days for first-episode genital herpes; 500 mg orally twice daily for 7 days for herpes zoster in immunocompromised patients; 500 mg orally twice daily for 7 days for recurrent mucocutaneous herpes in HIV patients.
200 mg orally twice daily for 10 days.
None Documented
None Documented
Terminal elimination half-life of penciclovir is approximately 2–3 hours in patients with normal renal function; extends to 9–18 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life approximately 5-7 hours in patients with normal renal function; prolonged in renal impairment (up to 24 hours in severe impairment).
Renal: 60–70% as penciclovir via tubular secretion and glomerular filtration; fecal: <10%; biliary: <1%.
Primarily renal excretion of unchanged drug (approx. 85%) with biliary/fecal elimination accounting for the remainder (approx. 15%).
Category C
Category C
Antiviral
Antiviral